Needham & Company
-
GenMark Diagnostics (GNMK) PT Raised to $19 at Needham & Company After Positive Preannouncement
-
GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
GenMark Diagnostics (GNMK) Prices 7.254M Share Common Offering at $9.65/Sh
-
GenMark Prices Public Offering of Common Stock
-
GenMark Prices Public Offering of Common Stock
-
GenMark Diagnostics (GNMK) PT Rises To $12 Despite Growing Pains
-
GenMark Diagnostics (GNMK) PT Lowered to $15 at Needham & Company Following ePlex Launch
-
GenMark Diagnostics (GNMK) PT Raised to $17 at Needham & Company; 'Announces 510(k) Clearance for ePlex & Respiratory Panel'
-
GenMark Diagnostics (GNMK) PT Raised to $17 at Needham & Company; Reiterates Buy
-
GenMark Diagnostics (GNMK): In Line With Preannouncement, Raising PT - Needham
-
Needham & Company Reiterates Buy Rating and $15 PT on GenMark Diagnostics (GNMK) Following In-Line Pre-Announcement
-
GenMark Diagnostics to Present at 16th Annual Needham Healthcare Conference
-
Needham & Company Reiterates Buy on GenMark Diagnostics (GNMK) Following 4Q
-
GenMark Diagnostics (GNMK) PT Raised to $15 at Needham & Company
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Needham & Company Raises Price Target as GenMark Diagnostics (GNMK) Prepares for Euro Launch
-
Needham & Company Reiterates a Buy Rating as GenMark Diagnostics (GNMK) Reports 4Q Results Consistent with Preannouncement
-
GenMark Diagnostics (GNMK) Pushes ePlex Launch to 2016; Needham & Company Cuts Price Target to $13
-
GenMark Diagnostics (GNMK) European ePlex Launch First of Many Catalysts, Needham & Company Says
-
GenMark Diagnostics (GNMK) PT Raised to $16 at Needham & Company
-
Needham & Company Comments on Sector Implications Amid Medtronic (MDT)/Covidien (COV) Megadeal
-
GenMark (GNMK) Bullish Stance Reiterated at Needham & Company on Solid Q1
-
Pre-Open Stock Movers 12/19: (ALIM) (AKS) (ORCL) Higher; (CIE) (GIG) (FB) Lower (more...)
-
Needham & Company Starts GenMark Diagnostics (GNMK) at Buy; Positive on NexGen Analyzer
-
Notable Analyst Rating Changes 07/12: QCOM, MSFT, YHOO, SNDK Upgraded; ACXM, GLW, MAR, MOLX Downgraded

